Interleukin-22 (IL-22), one of the cytokines secreted by T-helper 17 (Th17) cells, binds to a class II cytokine receptor containing an IL-22 receptor 1 (IL-22R1) and IL-10R2 and influences a variety of immune reactions. IL-22 has also been shown to modulate cell cycle and proliferation mediators such as extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK), but little is known about the underlying molecular mechanisms of IL-22 in tumorigenesis. In this paper, we propose that IL-22 has a crucial role to play in controlling epithelial cell proliferation and tumorigenesis in the breast. IL-22 increased MAP3K8 phosphorylation through IL-22R1, followed by the induction of MEK-ERK, JNK-c-Jun, and STAT3 signaling pathways. Furthermore, IL-22-IL-22R1 signaling pathway activated activator protein-1 and HER2 promoter activity. In addition, Pin1 was identified as a key positive regulator for the phosphorylation-dependent MEK, c-Jun and STAT3 activity induced by IL-22. Pin1 −/− mouse embryonic fibroblasts (MEF) exhibited significantly a decrease in IL-22induced MEK1/2, c-Jun, and STAT3 phosphorylation compared with Pin1 +/+ MEF. In addition, a knockdown of Pin1 prevented phosphorylation induced by IL-22. The in vivo chorioallantoic membrane assay also showed that IL-22 increased tumor formation of JB6 Cl41 cells. Moreover, the knockdown of MAP3K8 and Pin1 attenuated tumorigenicity of MCF7 cells. Consistent with these observations, IL-22 levels positively correlate with MAP3K8 and Pin1 expression in human breast cancer. Overall, our findings point to a critical role for the IL-22-induced MAP3K8 signaling pathway in promoting cancer-associated inflammation in the tumor microenvironment.
Introduction
Interleukin-22 (IL-22) is produced by innate lymphoid cells, Th17 cells and Th22 cells, particularly at mucosal surfaces (1) (2) (3) . IL-22 signaling takes place through a distinct class 2 receptor (IL-22R) that is composed of the subunits IL-22R1 (IL-22RA1) and IL-10R2 (IL-10RB2), which are independently shared with IL-20 and IL-24 and with IL-10 and IL-26, respectively (4, 5) . First, IL-22 binds to IL-22R1 and then the IL-22-IL-22R1 complex binds to IL-10R2 to propagate downstream signals (6) . IL-22R1 is absent in immune cells but is expressed within tissues, such as epithelial cells of pancreas, intestine, liver, lung and skin (1) . The important function of IL-22 in the promotion of antimicrobial immunity is in induction of antimicrobial peptides and tissue repair by induction of epithelial cell proliferation and survival. However, IL-22 can also promote pathological inflammatory responses in the skin or intestine in mouse models, and its concentration is increased in a variety of human diseases including psoriasis, rheumatoid arthritis, inflammatory bowel disease and cancer (1, 7) . In line with the pleiotropic roles of IL-22, it is known that this cytokine uses the Jak-STAT signal transduction pathway, inducing phosphorylation of the kinases Jak1 and Tyk2 and the STAT1, STAT3 and STAT5 transcription factors (4, 8) , which is important for tumor development (9) . However, the pathway regulated by IL-22 during tumor development and its functions needs to be understood, because both tumorinhibiting and tumor-promoting effects have been reported.
A serine/threonine protein kinase, mitogen-activated protein kinase kinase kinase 8 (MAP3K8), also known as COT, was originally identified as a target for proviral integration in MoMuLV-induced rat T-cell lymphomas and MMTV-induced mammary carcinomas (10, 11) . MAP3K8 belongs to the MAP3K family of proteins (12) . When overexpressed in cell lines, MAP3K8 activates the extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 MAPK pathways, all due to the ability of MAP3K8 to induce phosphorylation and activation of the respective MAP2K (12) (13) (14) . The overexpression of MAP3K8 also induces transcription of the IL-2 gene in T cells (15) . Moreover, stimulation of T cells with anti-CD3 antibodies along with an ectopic expression of MAP3K8 significantly enhances IL-2 production (16) . In addition, MAP3K8 plays an important role in IL-12 production and Th cell differentiation (17) , giving rise to a possibility that MAP3K8 may be an interesting target for the development of drugs to treat chronic inflammatory diseases. However, it is largely unknown whether MAP3K8 is also involved in the signaling pathway of IL-22 during tumor development.
Pin1, peptidyl-prolyl cis/trans isomerase, consists of two domains: a peptidyl-prolyl cis/trans isomerase domain at its C-terminus responsible for isomerization and a WW domain at its N-terminus that acts as a binding element specific to pSer/Thre-Pro motifs (18) (19) (20) . Through these two domains, Pin1 binds to and isomerizes specific pSer/Thr-Pro motifs and catalytically induces conformational changes after phosphorylation. Such conformational changes can have profound effects on the function of many Pin1 substrates, such as p53, cyclin D1, c-Jun, MEK1, nuclear factor-κB and STAT3, which results in its important roles in many cellular events, such as cell cycle progression and differentiation (21) (22) (23) (24) (25) (26) . Furthermore, Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun for tumorigenesis (23) . Although many details of the Pin1 function have been elucidated, little is known regarding whether Pin1 influences IL-22 signaling pathway during tumorigenesis. Therefore, uncovering the mechanisms responsible for the prolonged phosphorylation of IL-22-signalingrelated proteins becomes an important goal, given that constitutive signaling from Pin1 results in tumorigenesis.
In this paper, we have determined for the first time that MAP3K8 regulates the IL-22 signaling pathway. In this signaling pathway, IL-22 induced MAP3K8 phosphorylation, which increased the activity of ERK1/2, JNK1/2, and STAT3, resulting in the transcriptional activation of c-fos and c-jun. Furthermore, these IL-22-induced signaling pathways were enhanced by prolyl isomerase Pin1, whereas Pin1 knockdown attenuated IL-22-induced activator protein-1 (AP-1) activity and neoplastic cellular transformation. These results suggest that both MAP3K8 and Pin1 play an important role in promoting IL-22-induced tumorigenesis. MAP3K8 mediates IL-22-induced tumorigenesis 616373); 4-(3-chlor-4-fluorophenylamino)-6-(pyridin-3-yl-methylamino)-3-cyano-1,7-naphthylridine], PD98059 and SP600125 were purchased from Calbiochem-Novabiochem (San Diego, CA). Juglone (4-hydroxytamoxifen) and basal medium eagle were procured from Sigma-Aldrich (St Louis, MO). Cell proliferation enzyme-linked immunosorbent assay and BrdU (colorimetric) were from Roche Applied Science (Indianapolis, IN). The dualluciferase reporter assay kit was purchased from Promega (Madison, WI). The phospho-specific and total antibodies against MEK1/2 (41G9 and 9122), ERK1/2 (197G2 and 137F5), JNK1/2 (G9 and 9252) and STAT3 (9131 and 124H6) and phospho-specific antibodies against MAP3K8 (4491) and c-Jun (Ser 63) were acquired from Cell Signaling Technology, Inc. (Beverly, MA); antibody against IL-22R1 (06-1077) was from Millipore (Bedford, MA); and antibodies against Pin1 (G8), c-Jun (N), and MAP3K8 (M20) was from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-Xpress (R91025) antibody was obtained from Invitrogen. Anti-IL22 (106773) antibody was from Abacam (Cambridge, MA).
Materials and methods

Reagents and antibodies
Cell culture and small interference RNA JB6 Cl41 mouse epidermal cells and MDA-MB231 breast cancer cells were maintained in Eagle's minimal essential medium (MEM) supplemented with 5% fetal bovine serum (FBS) and 10% FBS, respectively. MCF7 human breast cancer cells and Pin1 −/− mouse embryonic fibroblast (MEF) cells, which were kindly provided by Dr Kun Ping Lu (Beth Israel Deaconess Medical Center, Harvard Medical School), were grown in Dulbecco's modified Eagle's medium supplemented with 10% FBS. All these cell lines were cultured and maintained at 37ºC in humidified air containing 5% CO 2 . Mouse IL-22RA1 (accession number: NM_178257), Pin1 (accession number: NM_006221) and MAP3K8 (accession number: NM_005204) were silenced by transfecting the ON-TARGETplus small interfering RNA (siRNA) SMART pool-specific or nonspecific control pool double-stranded RNA oligonucleotides (Dharmacon, Chicago, IL) using LipofectamineTM 2000 (Invitrogen).
Immunoblot analysis
The cells were disrupted in radioimmunoprecipitation assay (RIPA) lysis buffer. The proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene difluoride. The membranes were blocked and hybridized with the appropriate primary antibody overnight at 4°C. After hybridization with HRP (horseradish peroxidase)-conjugated secondary antibody from rabbits or mice, the protein bands were visualized using a chemiluminescence detection kit (Amersham HRP Chemiluminescent Substrates, Amersham Biosciences, Piscataway, NJ). For detecting chemiluminescence, LAS4000 (GE Healthcare Biosciences, Pittsburgh, PA) was used.
Cell proliferation assay (BrdU incorporation)
Cells were seeded (5 × 10 4 cells/well) in 96-well plates in 100 µl of 5% FBS-MEM. After 24 h, they were treated with or without IL-22 for 48 h, labeled with 10 µl/well BrdU labeling solution, and then incubated for 4 h at 37°C in a 5% CO 2 atmosphere. Cell proliferation was estimated by measuring the absorbance at 370 nm.
Anchorage-independent cellular transformation assay (soft agar assay)
The effect of IL-22 on cell transformation was investigated in JB6 Cl41 cells and MCF7 cells. Briefly, 8 × 10 3 cells were exposed to different doses of IL-22 in 1 ml of 0.3% basal medium Eagle agar containing 10% FBS, 2 mM l-glutamine, and 25 µg/ml gentamicin. The cultures were maintained at 37°C in a 5% CO 2 incubator for 14-18 days, and cell colonies were scored using an Axiovert 200 M fluorescence microscope and Axio Vision software (Carl Zeiss, Thornwood, NY).
Reporter gene assays
For detecting firefly luciferase activity, the reporter gene assay was performed using lysates from AP-1-, c-jun-, c-fos-, or Her2-luc-transfected JB6 Cl41 cells. The reporter gene vector pRL-TK-luciferase plasmid (Promega) was cotransfected into each cell line and the renilla luciferase activity generated by this vector was used to normalize the results for transfection efficiency. Cell lysates were mixed with luciferase assay II reagent, and firefly luciferase light emission was measured by GloMax ® -Multi Detection System (Promega). Subsequently, renilla luciferase substrate was added to normalize the firefly luciferase data. The c-fos-luc promoter (pFos-WT GL3) and c-junluc promoter (JC6GL3) constructs were kindly provided by Dr Ron Prywes (Columbia University, New York, NY). The AP-1 luciferase reporter plasmid (−73/+63 collagenase-luciferase) was kindly provided by Dr Dong Zigang (Hormel Institute, University of Minnesota, Austin, MN).
Chorioallantoic membrane assay
Briefly, fertilized chicken eggs were transferred to an egg incubator and allowed to grow for 10 days. After this, the IL-22-treated JB6 Cl41 cells (1 × 10 7 ) were placed on the exposed chorioallantoic membrane (CAM), and the eggs were incubated in a humidified incubator at 37°C for 5-6 days. After 5-6 days, images were digitally recorded at 15× magnification with an SZ-61 zoom stereomicroscope (Olympus, Center Valley, PA). Tumor areas were analyzed with ImageJ digital imaging software (downloaded from the National Institutes of Health website).
Tumor samples
Among the women who underwent mastectomy for infiltrating duct carcinoma at Chosun University Hospital (Gwangju, Korea) from January 1990 to June 1996, the present study was done in 40 patients (age range: 42-72) whose paraffin-embedded tissues were relatively well preserved. Informed consent was obtained from all patients, and research protocols were approved by the ethics committee of Chosun University Hospital.
Immunohistochemical staining
All tumors investigated in the study were tested for Pin1, IL-22 and COT mouse monoclonal antibody (Santa Cruz Biotechnology). Immunolocalization for each antibody was performed using a Polink-2 HRP plus mouse diaminobenzidene detection system (Golden Bridge International, WA) according to the supplier's protocol. Briefly, 4 μm thick sections obtained after formalin fixation and paraffin embedding were deparaffinized in xylene and rehydrated with distilled water through graded concentrations of ethanol. Then the sections were placed in a glass jar with 10 mM citrate buffer (pH 6.0) and irradiated in a microwave oven for 15 min, and cooled down in the jar at room temperature for 20 min. After quenching the endogenous peroxidase activity in 0.3% hydrogen peroxide for 10 min, the slides were rinsed with distilled water. Then, the slides were rinsed with Tris-buffered saline (TBS) and blocking reagent was added for 10 min. After tapping off excess blocking reagent and carefully wiped around specimen, slides were incubated for 1 h with anti-Pin1 (G8) and -MAP3K8 (M20) antibodies (Santa Cruz Biotechnology) and overnight with anti-IL-22 (106773) antibody (Abacam) in a moist chamber at 37°C. After washing with TBS, mouse antibody enhancer was applied for 10 min, followed by washing with TBS as before. Then, polymer-HRP for mouse was applied for 10 min to cover each section. After washing with TBS, the localization of antibodies was visualized by incubating the sections for 5 min in a diaminobenzidene and counterstaining with Mayer's hematoxylin for 10 s. Distinct nuclear staining for Pin1 and cytoplasmic staining for COT and IL-22 were considered as positive immune reactivity.
Xenograft model
Six-week-old female BALB/c mice (18-20 g) were obtained from Samtako Co. (Korea), acclimatized for 1 week, and maintained in a clean room at the College of Pharmacy, Chosun University. Animals were caged under filtered pathogen-free air, fed commercial rat chow (Purina, Korea) and access to water ad libitum at a temperature between 20 and 23°C with 12 h light and dark cycles and a relative humidity of 50%. The protocols of the animal studies were approved by the Animal Care Committee of Chosun University (Gwangju, Korea). Mouse (n = 60) was randomly divided into three groups of 20 animals each. Then 4T1 metastatic mouse breast carcinoma cells were injected into the mammary gland of the mice in presence or absence of IL-22 and 100 μM TKI and then allowed to grow until the formation of tumors (14 days). The mice were observed daily for tumor growth. The tumor volume was calculated by the formula: V = (ab 2 )/2, in which 'a' is the longest diameter and 'b' is the shortest diameter of the tumor.
Statistical analysis
Fisher's exact test with two-sided probability values (P < 0.001) was used to analyze the correlation between IL-22, MAP3K8, and Pin1 in breast cancer patients. Data from reporter gene assay and soft agar assay were analyzed statistically using unpaired t-tests, and P values < 0.05 were considered significant. Statistical calculations were carried out with Prism Macintosh 4.0 (GraphPad Software, La Jolla, CA). Results are expressed as the mean ± standard error of triplicate measurements of three independent experiments.
Results
IL-22 promotes anchorage-independent transformation and tumorigenesis of JB6 Cl41 cells
To examine the effects of IL-22 on cell proliferation and anchorageindependent cell transformation, BrdU incorporation assay and soft agar assay were performed. We found that IL-22 treatment significantly and dose-dependently induced the cell proliferation of JB6 Cl41 cells ( Figure 1A ). Furthermore, IL-22 treatment dose-dependently increased not only colony numbers but also colony sizes in JB6 Cl41 cells ( Figure 1B-D) . To determine whether IL-22 affects tumorigenesis in vivo, CAM assay with JB6 Cl41 cells was performed. Representative images of CAM are shown ( Figure 1E ). For statistical evaluation, tumor section images were digitally recorded and tumor areas were analyzed ( Figure 1F ). The results showed that IL-22 significantly induced an increase in the tumor area compared with untreated control groups. Collectively, these results suggest that IL-22 induces the neoplastic cell transformation and tumorigenesis of JB6 Cl41 cells in vitro and in vivo.
IL-22 activates MEKs-ERKs and JNKs-c-Jun signaling via MAP3K8
The MAPK signaling pathway not only promotes cell proliferation but also mediates cell survival and is upregulated in various cancer cells (27) . To determine whether IL-22 regulates MAPK signaling pathways through MAP3K8 activation, JB6 Cl41 cells were treated with IL-22 and immunoblotting was conducted with specific antibody for phospho-MAP3K8 (Ser400). The results showed that IL-22 markedly induced the phosphorylation of MAP3K8 in a dose-and timedependent manner (Figure 2A and B). To further examine whether MAP3K8 activation is mediated by IL-22R1, JB6 Cl41 cells were transfected with siRNA-IL-22R1, and then treated with IL-22. The results showed that the knockdown of IL-22R1 suppressed the phosphorylation of MAP3K8 induced by IL-22 compared with control cells ( Figure 2C ). Since MAP3K8 is an upstream kinase of MEK1/2 and JNK1/2 (12, 28) , we examined the effects of IL-22 on the MEKs-ERKs and JNKs-c-Jun signaling pathway. The results showed that IL-22 induced phosphorylation of MEK1/2 and ERK1/2 both in terms of dose and time dependence ( Figure 2D and E) as well as that of JNK1/2 and c-Jun ( Figure 2F and G). Furthermore, treatment with TKI, a MAP3K8 kinase inhibitor, inhibited the phosphorylation of MAP3K8, MEK1/2, ERK1/2, JNK1/2 and c-Jun induced by IL-22 ( Figure 2H ). Similarly, PD98059, a MEK1/2 inhibitor and SP600125, a JNK inhibitor, also inhibited the phosphorylation of ERK1/2 and c-Jun induced by IL-22 ( Figure 2I ), thus suggesting that MAP3K8 regulates the signaling pathways of MEKs-ERKs and JNKs-c-Jun induced by IL-22 through the IL-22R1 in JB6 Cl41 cells.
IL-22 activates STAT3 through activation of MAP3K8
Accumulated evidences suggest that IL-22 promotes tumor growth and metastasis by STAT3 activation (7, 29) . To determine whether STAT3 activation induced by IL-22 is mediated by MAP3K8, we first examined the IL-22-induced phosphorylation of STAT3 in JB6 Cl41 cells. The results showed that IL-22 dose-and time-dependently increased the phosphorylation of STAT3 in JB6 Cl41 cells ( Figure 3A and B). In addition, the IL-22-induced phosphorylation of STAT3 was suppressed in siRNA-IL-22R1-transfected cells compared with siRNA-control-transfected cells ( Figure 3C ). To examine the effects of knockdown of MAP3K8 on the STAT3 activation, JB6 Cl41 cells were transfected with either siRNA-control or siRNA-MAP3K8, and then exposed to IL-22. The results showed that the knockdown of MAP3K8 inhibited the IL-22-induced phosphorylation of STAT3 ( Figure 3D ). Furthermore, TKI inhibited the phosphorylation of STAT3 as well as MAP3K8 induced by IL-22 in a dose-dependent manner ( Figure 3E ), indicating that MAP3K8 positively regulates STAT3 signaling pathway induced by IL-22.
Pin1 required for the phosphorylation-dependent MEKs, c-Jun and STAT3 activity induced by IL-22
Given that Pin1, which specifically recognizes the pSer/Thr-Pro motifs on its target proteins, interacts with MEK1 (30), c-Jun (23) and STAT3 (26), we next examined whether IL-22 signaling is regulated by Pin1. The Pin1 −/− MEF cells were transfected with Xpress-Pin1 and exposed to IL-22. The results showed that the levels of MEK1/2, c-Jun and STAT3 phosphorylation were considerably increased by Pin1 overexpression in the Pin1 -/-MEF cells ( Figure 4A ). In addition, Pin1 overexpression was found to markedly enhance IL-22-induced phosphorylation of MEK1/2, c-Jun and STAT3 ( Figure 4A ). To further confirm the regulatory role of Pin1 on the phosphorylation of MEK1/2, c-Jun and STAT3, mock-or Pin1-overexpressing JB6 Cl41 cells were exposed to IL-22 and immunoblotting was performed with the respective antibodies. There was an increase in the level of MEK1/2, c-Jun, and STAT3 phosphorylation in Pin1-overexpressing cells compared with control cells ( Figure 4B ). To determine whether knockdown of Pin1 suppresses the IL-22-induced phosphorylation of MEK1/2, c-Jun and STAT3, JB6 Cl41 cells were transfected with siRNA-Pin1 and treated or not treated with IL-22. The IL-22-induced phosphorylation of MEK1/2, c-Jun and STAT3 was attenuated in Pin1-knockdown cells ( Figure 4C ). Also, on treatment with juglone, a Pin1 inhibitor, the IL22-induced phosphorylation of MEK1/2, c-Jun, and STAT3 in JB6 Cl41 cells was found to be inhibited ( Figure 4D ). Overall, these results indicate that Pin1 enhances the IL22-induced phosphorylation of MEK1/2, c-Jun, and STAT3.
MAP3K8 and Pin1 are required for IL-22-induced AP-1 and cell transformation in JB6 Cl41 cells
The AP-1 transcription factor is a dimeric complex of homo-or heterodimers of Jun, Fos, activating transcription factor, and musculoaponeurotic fibrosarcoma protein family members that are activated by MAPK signaling pathway (31, 32) . To determine the effects of IL-22 on the AP-1 activity, we examined the effects of IL-22 on the c-fos and c-jun promoter. The transcriptional activity of c-fos and c-jun was significantly increased by treatment with IL-22 in JB6 Cl41 in a dose-dependent manner ( Figure 5A and B ). In addition, treatment , harvested and lysed. The lysates were resolved by SDS-PAGE and immunoblotting analysis was performed using specific antibodies against the corresponding proteins. (H) Cells were serum starved for 24 h, pretreated with the indicated concentrations of TKI for 2 h, exposed to 25 ng/ml IL-22 for 15 min, harvested and lysed. The lysates were resolved by SDS-PAGE and immunoblotting analysis was performed using specific antibodies against the corresponding proteins. (I) Cells were serum starved for 24 h, treated with either PD98059 (upper panel) or SP600125 (lower panel). At 1 h after pretreatment, cells were exposed to 25 ng/ml IL-22 for 15 min, harvested and lysed. The lysates were resolved by SDS-PAGE and immunoblotting analysis was performed using specific antibodies against the corresponding proteins. (E) Cells were serum starved for 24 h, pretreated with the indicated concentrations of TKI for 2 h and then exposed to 25 ng/ml IL-22 for 15 min, harvested and lysed. The lysates were resolved by SDS-PAGE and immunoblotted using specific antibodies against the corresponding proteins. harvested, and lysed. The lysates were resolved by SDS-PAGE and immunoblotting analysis was performed using specific antibodies against the corresponding proteins. (D) JB6 Cl41 cells were serum starved for 24 h, pretreated with the indicated concentrations of juglone for 2 h and then exposed to 25 ng/ml IL-22 for 15 min, harvested and lysed. The lysates were resolved by SDS-PAGE and immunoblotting analysis was performed using specific antibodies against the corresponding proteins. with IL-22 was found to significantly induce AP-1 transactivation in JB6 Cl41 ( Figure 5C ). Since a cis-acting element of HER2 promoter is regulated by STAT3 signaling (33) , we next examined the effect of IL-22 on HER2 promoter activity in JB6 Cl41 cells. The results showed that IL-22 treatment significantly enhanced HER2 promoter activity ( Figure 5D ). To further confirm that MAP3K8 and Pin1 cooperatively regulated AP-1 and HER2 promoter activated by IL-22, we assessed IL-22-induced AP-1 and HER2 activity in the presence or absence of TKI and/or juglone in JB6 Cl41 cells. As expected, the TKI and juglone treatment inhibited the IL-22-induced AP-1 ( Figure 5E ) and HER2 ( Figure 5F ) promoter activity in JB6 Cl41 cells. Taken together, these results strongly support the idea that IL-22-induced AP-1 and HER2 promoter activity is mediated by MAP3K8 signaling and enhanced by Pin1.
MAP3K8 mediates IL-22-induced tumorigenesis
To investigate whether MAP3K8 and Pin1 are essential for IL-22induced epithelial cell transformation, we first examined the effect of TKI and juglone on IL-22-induced cell transformation of JB6 Cl41 cells. The results showed that the TKI and juglone treatment significantly inhibited the IL-22-induced cell transformation ( Figure 5G ). Furthermore, TKI and juglone decreased not only colony numbers ( Figure 5H ) but also colony sizes ( Figure 5I ). To further determine the effects of TKI and juglone on the IL-22-induced cell transformation in vivo, a CAM assay was performed with JB6 Cl41 cells. Representative images of CAM ( Figure 5J ) are shown. For statistical evaluation, tumor section images were digitally recorded and tumor areas were analyzed ( Figure 5K ). The results indicated that both TKI and juglone significantly suppressed IL-22-induced cell transformation compared with untreated control groups in CAM ( Figure 5J and K). Overall, these results suggest that MAP3K8 and Pin1 are essential for IL-22-induced epithelial cell transformation of JB6 Cl41 cells in vitro and in vivo.
IL-22 levels positively correlate with MAP3K8 and Pin1 expression in human breast cancer
To further understand the pathological relevance of IL-22 in breast tumorigenesis, we next examined the expression of IL-22 in human breast tumors. Knowing that MAP3K8 mediated the IL-22-induced MAPK signaling and Pin1 enhanced such signaling, immunohistochemistry was performed on human breast cancer tissues using IL-22, MAP3K8 and Pin1 antibodies. Five of the nine breast cancer samples that had a low amount of IL-22 presented with a lower expression both MAP3K8 and Pin1, whereas 27 of the 31 breast cancer samples that contained a high amount of IL-22 correspondingly had a higher expression of both MAP3K8 and Pin1 ( Figure 6A-C) . Eight of the 11 breast cancer samples that contained a low amount of MAP3K8 also had a lower expression of Pin1, whereas all 29 breast cancer samples that contained a higher amount of MAP3K8 had a correspondingly high expression of Pin1, indicating that most tumors containing high levels of MAP3K8 also had markedly increased levels of Pin1 ( Figure 6A and D) . Using The Human Protein Atlas (http://www.proteinatlas.org) (34), we observed similar Pin1 and MAP3K8 expression characteristics in human breast duct carcinomas, with pronounced expression in most carcinoma cells (data not shown). Furthermore, immunoreactivity for IL-22 was observed in both CD45 + and CD68 − cells, presumably lymphocytes, whereas immunoreactivity for Pin1 as well as MAP3K8 was positive in cytokeratin AE1/AE3 expressing cells, presumably epithelial cells (data not shown). Therefore, we examined the effect of IL-22 on the signaling pathway of MAP3K8, MEKs, JNKs and STAT3 in MCF7 and MDA-MB231 cells. The results showed that IL-22 markedly induced the phosphorylation of MAP3K8, resulting in activation of MEKs-ERK, JNKs-c-Jun and STAT3 signaling pathways, respectively ( Figure 6E ). To determine whether MDA-MB231 cells were susceptible to IL-22-induced cell proliferation and transformation, we first examined the effect of IL-22 on cell proliferation by BrdU incorporation assay. The result showed that treatment with IL-22 significantly induced the cell proliferation, whereas treatment of TKI and juglone significantly inhibited the IL-22-induced cell proliferation in MDA-MB231 cells, respectively ( Figure 6F ). Thereafter, we studied the correlation between MAP3K8 as well as Pin1 activity and IL-22 on tumorigenicity of MCF7 and MDA-MB231 cells using soft agar assay. The results showed that treatment of TKI and juglone significantly inhibited the colony formation of MCF7 and MDA-MB231 cells ( Figure 6G ). Furthermore, depletion of MAP3K8 and Pin1 in MCF7 cells profoundly reduced the tumor growth induced by IL-22 compared with untreated control group ( Figure 6H) . The effects of MAP3K8 on IL-22-induced tumor development in vivo were studied in a nude mice xenograft model with 4T1 metastatic mouse breast carcinoma cells. Then 4T1 cells were separately injected into the mammary gland of the BALB/c mice in presence or absence of TKI and IL-22, respectively. Representative tumor images demonstrated that IL-22 significantly induced the mammary gland tumor development, whereas treatment of TKI significantly inhibited the mammary gland tumor development, suggested that MAP3K8 might play important role for IL-22-induced mammary tumorigenesis ( Figure 6I and J).
Discussion
Tumor microenvironments that lead to a growth stimulation effect in malignancy include a large population of tumor cells, malignant transforming cells, immune cells, and macrophages (35) . Given that there is an increasing amount of evidence for the tumor microenvironment, it has recently been proposed as a target for therapy (36, 37) . But the application of chemoprevention to control the tumor microenvironment during the early stages of carcinogenesis has not received concerted attention so far. In our study, we provide the first direct evidence that IL-22 leads to the activation of MAP3K8, which results in the induction of epithelial transformation through its downstream AP-1 signaling pathways. We also demonstrate that Pin1 enhances the phosphorylation of MEK1/2, c-Jun and STAT3 induced by IL-22. Taken together with our increasing understanding of IL-22-IL-22R1 signaling pathway, this work highlights how MAP3K8 as well as Pin1 regulate IL-22-induced tumorigenicity.
Upon growth factor stimulation, the pathway from Ras through Raf and mitogen-activated protein (MAP) kinase kinase (MKK, also called MEK) to ERK/MAPK regulates many fundamental cellular processes that govern the cell transformation, differentiation, proliferation, and survival (38, 39) . Moreover, the active Ras/Raf/MEK/ERK pathway invariably presents the hallmark of malignant phenotypes: abnormal cell growth, invasion, and angiogenesis (40) . Interestingly, lipopolysaccharide, a component of Gram-negative bacteria, and the proinflammatory cytokines tumor necrosis factor α and interleukin-1 (IL-1) do not require Raf but distinct MAP3K8 to promote tumor development and growth (41) (42) (43) (44) . Moreover, the activation of MAP3K8 is required for the lipopolysaccharide-induced production of tumor necrosis factor alpha or IL-1β in T-cell lines, which is achieved by activating the transcription factors NFAT (nuclear factor of activated T-cells) and nuclear factor-kappaB (44, 45) , suggesting that MAP3K8 may be an interesting target for the development of drugs to treat chronic inflammatory diseases and cancer. It was reported that MAP3K8 is a potent serine threonine kinase, which, when overexpressed, activates the MAPK and SAPK pathway (12) and is overexpressed in human breast cancer (46) . MAP3K8 also induces cell transformation through upregulation of c-fos transcriptional activity (47) . Moreover, the IL-17A-activated MAP3K8 appears to function upstream of MEK/ERK and JNK/c-Jun, which leads to induction of neoplastic cellular transformation through its downstream AP-1 signaling pathways (48) . Despite the vital role of MAP3K8 in tumor development, the precise mechanisms that regulate IL-22 signaling pathway in carcinogenesis have not been well explored yet. In our study, we found that IL-22 strongly induced phosphorylation of MAP3K8 at Ser400, followed by the activation of MEKs-ERKs and JNKs-c-Jun signaling pathways. In addition, the knockdown of IL-22R1 lowered the MAP3K8 phosphorylation induced by IL-22, indicating that MAP3K8 activation depends on the IL-22 signaling pathway through the IL-22 receptor. Moreover, treatment of TKI, a MAP3K8 inhibitor, strongly suppressed the signaling pathways of MEK-ERK and JNK-c-Jun induced by IL-22, resulted from the inhibition of MAP3K8 phosphorylation. Overall, these data indicated that MAP3K8 functions as an important mediator of MAP3K8 mediates IL-22-induced tumorigenesis IL-22-IL-22R1 signaling pathway. A previous study had demonstrated that IL-22 increases the expression of many antiapoptotic and mitogenic proteins following the activation of STAT3 (29) . This observation is in agreement with a recent report showing that IL-22 can be found in the microenvironment of hepatocellular carcinoma, and it results in tumor growth, inhibition of apoptosis, and promotion of metastasis due to STAT3 activation (7) . In the current study, we found that IL-22-induced STAT3 signaling pathway through the phosphorylation of MAP3K8 resulted in the induction of HER2 promoter activity. These results suggested that MAP3K8 might play a pivotal role in IL-22-induced STAT3 activation for tumor growth.
The phosphorylation of proteins on serine or threonine residues that immediately precede proline resides (Ser/Thr-Pro) is an important signaling mechanism for cell cycle regulation, transcription, cell differentiation, and proliferation (49) . By binding to and isomerizing peptidyl-prolyl bond in specific phosphorylated Ser/Thr-Pro motifs, prolyl isomerase Pin1 induces conformational changes in its target proteins (20) . These conformational changes can have profound effects on the Pin1 substrate functioning, resulting in modulation of their activity, change in phosphorylation status, modification of protein-protein interaction, altered subcellular localization and decreased stability (50) . It was reported that Pin1 regulates MAPK and STAT3 signaling pathway in breast tumor development through its interaction with MEK1 (24), c-Jun (23), and STAT3 (26) . These reports supported our hypothesis that high levels of Pin1 may regulate IL-22-induced signaling pathway, leading to tumor progression in breast cancer. Therefore, we examined the molecular events that are mediated by Pin1 after mitogen activation by IL-22 in MCF7 cells. The data provide the first evidence that Pin1 regulates the IL-22induced signaling pathway in such a way as to increase the phosphorylation of MEK1/2, c-Jun, and STAT3, thus resulting in an increased AP-1 and HER2 promoter activity and neoplastic cellular transformation. Subsequently, the in vivo CAM assay with JB6 cells showed that IL-22-induced tumorigenesis and the inhibition of Pin1 activity significantly reduced the tumor growth induced by IL-22.
Although the role of IL-22 in tumorigenesis has been demonstrated, the physiological significance of IL-22 in breast cancer is not yet elucidated. To further understand the role of IL-22 in breast tumorigenesis, we performed immunohistochemical analysis on human breast cancer tissues using IL-22, MAP3K8, and Pin1 antibodies. Our results show that IL-22 levels correlate positively with MAP3K8 as well as Pin1 expression in breast cancer tissues. These results define an IL-22 signaling that conveys an oncogenic signal to promote aggressiveness in human breast cancer through the induction of MAP3K8 and Pin1 activity. Consistent with these observations, our results also showed that knockdown of MAP3K8 and Pin1 decreased tumorigenicity of MCF7 cells, suggesting that MAP3K8 and Pin1 might be important molecular targets for the development of breast cancer by IL-22. This study documents a previously unknown role of IL-22 in human breast cancer by showcasing its promotional role in proliferation, cell survival, transformation and tumor development. Moreover, these results make MAP3K8 and Pin1 attractive therapeutic targets in tumor microenvironment, inhibition of which could potentially attenuate the aggressiveness of breast cancer. Hence, our study not only reveals a novel mechanism underlying the IL-22 activity but also provides a novel treatment strategy against metastatic breast cancer.
